Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tivic Health Systems, Inc. is a medical technology and consumer bioelectronic health company focused on developing non-invasive neuromodulation therapies. The company operates at the intersection of medical devices, bioelectronic medicine, and consumer health technology, with an emphasis on addressing chronic conditions through targeted electrical stimulation. Tivic Health’s products are designed to modulate neural pathways associated with inflammation and autonomic nervous system function.
The company’s primary revenue driver historically has been its FDA-cleared consumer device, ClearUP®, which is marketed for sinus pain and congestion relief. Tivic Health positions itself as a developer of clinically validated, non-pharmaceutical therapies that can be used at home. The company was founded in 2016 and went public in 2021 through an initial public offering, positioning itself to expand beyond consumer wellness into regulated therapeutic indications supported by clinical research.
Business Operations
Tivic Health operates primarily through two business areas: consumer bioelectronic devices and clinical-stage therapeutic development. Revenue to date has been largely generated from sales of the ClearUP® sinus pain relief device, which is sold directly to consumers through e-commerce channels and selected retail and distribution partners in the United States.
In parallel, the company is advancing proprietary neuromodulation technology platforms intended for prescription or regulated use in inflammatory and neurological conditions. Tivic Health controls its core intellectual property related to vagus nerve and autonomic nervous system stimulation. As of publicly available disclosures, manufacturing is outsourced, and there are no material joint ventures reported. International commercial operations remain limited, with most revenue derived from domestic U.S. sales.
Strategic Position & Investments
Strategically, Tivic Health is pursuing a transition from a single-product consumer device company toward a diversified bioelectronic medicine platform. Growth initiatives have centered on expanding clinical research programs aimed at validating its neuromodulation technology for conditions such as inflammatory and immune-related disorders. These efforts are intended to support future regulatory submissions and potential prescription-based products.
The company has made selective investments in research and development rather than large-scale acquisitions. Public filings indicate no major completed acquisitions of operating companies as of the most recent reporting periods. Tivic Health’s strategy emphasizes leveraging existing technology and intellectual property into new therapeutic indications rather than geographic expansion or consolidation through mergers.
Geographic Footprint
Tivic Health is headquartered in the United States, with corporate operations based in California. Its commercial activities are primarily concentrated in North America, where the ClearUP® device is marketed and sold.
International presence is limited, with no material overseas manufacturing facilities or regional offices disclosed in public filings. Any international sales or distribution arrangements have not been reported as a significant contributor to revenue. As such, the company’s operational and investment footprint remains predominantly U.S.-focused.
Leadership & Governance
Tivic Health was founded by experienced medical device entrepreneurs, and its leadership team combines expertise in healthcare technology, regulatory strategy, and commercialization. The company’s governance structure follows standard U.S. public company practices, with oversight by a board of directors and compliance with SEC reporting requirements.
Key executives include:
- Jennifer Ernst – Chief Executive Officer
- Ken Driscoll – Chief Financial Officer
- Blake Gurfein, MD – Chief Medical Officer
- Eric Salzman – Chief Operating Officer
Management has articulated a strategic vision centered on advancing non-invasive neuromodulation as a credible alternative or complement to pharmaceutical treatments, supported by clinical evidence and regulatory validation.